The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bioequivalent Peptide Drugs Market Research Report 2025
Synopsis
A bioequivalent peptide drug is one that has similar structure and function, and exhibits similar pharmacokinetic and pharmacodynamic properties in vivo to the original brand drug or an approved reference product. These drugs are usually synthesized through genetic recombination technology and undergo rigorous research and development and approval procedures.
Global Bioequivalent Peptide Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Bioequivalent Peptide Drugs market research.
The development and production of bioequivalent peptide drugs usually requires detailed comparison and analysis, including in vitro and in vivo experimental evaluation, and comparison of clinical trial data. Bioequivalent peptide drugs have a wide range of applications in drug replacement, therapeutic expansion, and biosimilars.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Bioequivalent Peptide Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Eli Lilly and Company
Alvogen
Pfenex
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Ambio Pharmaceuticals
Jiangsu Sinopep Allsino Biopharmaceutical
Shanghai Shyndec Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Shanghai United Cell Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide Biotechnology
Segment by Type
Teriparatide(Forteo)
Teduglutide(Gattex)
Liraglutide(Victoza)
Segment by Application
Short Bowel Syndrome
Osteoporosis
Type 2 Diabetes
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Bioequivalent Peptide Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
A bioequivalent peptide drug is one that has similar structure and function, and exhibits similar pharmacokinetic and pharmacodynamic properties in vivo to the original brand drug or an approved reference product. These drugs are usually synthesized through genetic recombination technology and undergo rigorous research and development and approval procedures.
Global Bioequivalent Peptide Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Bioequivalent Peptide Drugs market research.
The development and production of bioequivalent peptide drugs usually requires detailed comparison and analysis, including in vitro and in vivo experimental evaluation, and comparison of clinical trial data. Bioequivalent peptide drugs have a wide range of applications in drug replacement, therapeutic expansion, and biosimilars.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Bioequivalent Peptide Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Eli Lilly and Company
Alvogen
Pfenex
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Ambio Pharmaceuticals
Jiangsu Sinopep Allsino Biopharmaceutical
Shanghai Shyndec Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Shanghai United Cell Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide Biotechnology
Segment by Type
Teriparatide(Forteo)
Teduglutide(Gattex)
Liraglutide(Victoza)
Segment by Application
Short Bowel Syndrome
Osteoporosis
Type 2 Diabetes
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Bioequivalent Peptide Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Bioequivalent Peptide Drugs Market Overview
1.1 Product Overview and Scope of Bioequivalent Peptide Drugs
1.2 Bioequivalent Peptide Drugs Segment by Type
1.2.1 Global Bioequivalent Peptide Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Teriparatide(Forteo)
1.2.3 Teduglutide(Gattex)
1.2.4 Liraglutide(Victoza)
1.3 Bioequivalent Peptide Drugs Segment by Application
1.3.1 Global Bioequivalent Peptide Drugs Market Value by Application: (2023-2029)
1.3.2 Short Bowel Syndrome
1.3.3 Osteoporosis
1.3.4 Type 2 Diabetes
1.3.5 Others
1.4 Global Bioequivalent Peptide Drugs Market Size Estimates and Forecasts
1.4.1 Global Bioequivalent Peptide Drugs Revenue 2018-2029
1.4.2 Global Bioequivalent Peptide Drugs Sales 2018-2029
1.4.3 Global Bioequivalent Peptide Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Bioequivalent Peptide Drugs Market Competition by Manufacturers
2.1 Global Bioequivalent Peptide Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Bioequivalent Peptide Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Bioequivalent Peptide Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Bioequivalent Peptide Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Bioequivalent Peptide Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bioequivalent Peptide Drugs, Product Type & Application
2.7 Bioequivalent Peptide Drugs Market Competitive Situation and Trends
2.7.1 Bioequivalent Peptide Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bioequivalent Peptide Drugs Players Market Share by Revenue
2.7.3 Global Bioequivalent Peptide Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bioequivalent Peptide Drugs Retrospective Market Scenario by Region
3.1 Global Bioequivalent Peptide Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Bioequivalent Peptide Drugs Global Bioequivalent Peptide Drugs Sales by Region: 2018-2029
3.2.1 Global Bioequivalent Peptide Drugs Sales by Region: 2018-2023
3.2.2 Global Bioequivalent Peptide Drugs Sales by Region: 2024-2029
3.3 Global Bioequivalent Peptide Drugs Global Bioequivalent Peptide Drugs Revenue by Region: 2018-2029
3.3.1 Global Bioequivalent Peptide Drugs Revenue by Region: 2018-2023
3.3.2 Global Bioequivalent Peptide Drugs Revenue by Region: 2024-2029
3.4 North America Bioequivalent Peptide Drugs Market Facts & Figures by Country
3.4.1 North America Bioequivalent Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Bioequivalent Peptide Drugs Sales by Country (2018-2029)
3.4.3 North America Bioequivalent Peptide Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bioequivalent Peptide Drugs Market Facts & Figures by Country
3.5.1 Europe Bioequivalent Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Bioequivalent Peptide Drugs Sales by Country (2018-2029)
3.5.3 Europe Bioequivalent Peptide Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bioequivalent Peptide Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Bioequivalent Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Bioequivalent Peptide Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Bioequivalent Peptide Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bioequivalent Peptide Drugs Market Facts & Figures by Country
3.7.1 Latin America Bioequivalent Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Bioequivalent Peptide Drugs Sales by Country (2018-2029)
3.7.3 Latin America Bioequivalent Peptide Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bioequivalent Peptide Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Bioequivalent Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Bioequivalent Peptide Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Bioequivalent Peptide Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bioequivalent Peptide Drugs Sales by Type (2018-2029)
4.1.1 Global Bioequivalent Peptide Drugs Sales by Type (2018-2023)
4.1.2 Global Bioequivalent Peptide Drugs Sales by Type (2024-2029)
4.1.3 Global Bioequivalent Peptide Drugs Sales Market Share by Type (2018-2029)
4.2 Global Bioequivalent Peptide Drugs Revenue by Type (2018-2029)
4.2.1 Global Bioequivalent Peptide Drugs Revenue by Type (2018-2023)
4.2.2 Global Bioequivalent Peptide Drugs Revenue by Type (2024-2029)
4.2.3 Global Bioequivalent Peptide Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Bioequivalent Peptide Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Bioequivalent Peptide Drugs Sales by Application (2018-2029)
5.1.1 Global Bioequivalent Peptide Drugs Sales by Application (2018-2023)
5.1.2 Global Bioequivalent Peptide Drugs Sales by Application (2024-2029)
5.1.3 Global Bioequivalent Peptide Drugs Sales Market Share by Application (2018-2029)
5.2 Global Bioequivalent Peptide Drugs Revenue by Application (2018-2029)
5.2.1 Global Bioequivalent Peptide Drugs Revenue by Application (2018-2023)
5.2.2 Global Bioequivalent Peptide Drugs Revenue by Application (2024-2029)
5.2.3 Global Bioequivalent Peptide Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Bioequivalent Peptide Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Eli Lilly and Company
6.1.1 Eli Lilly and Company Corporation Information
6.1.2 Eli Lilly and Company Description and Business Overview
6.1.3 Eli Lilly and Company Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Eli Lilly and Company Bioequivalent Peptide Drugs Product Portfolio
6.1.5 Eli Lilly and Company Recent Developments/Updates
6.2 Alvogen
6.2.1 Alvogen Corporation Information
6.2.2 Alvogen Description and Business Overview
6.2.3 Alvogen Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Alvogen Bioequivalent Peptide Drugs Product Portfolio
6.2.5 Alvogen Recent Developments/Updates
6.3 Pfenex
6.3.1 Pfenex Corporation Information
6.3.2 Pfenex Description and Business Overview
6.3.3 Pfenex Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfenex Bioequivalent Peptide Drugs Product Portfolio
6.3.5 Pfenex Recent Developments/Updates
6.4 HEC Pharm
6.4.1 HEC Pharm Corporation Information
6.4.2 HEC Pharm Description and Business Overview
6.4.3 HEC Pharm Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 HEC Pharm Bioequivalent Peptide Drugs Product Portfolio
6.4.5 HEC Pharm Recent Developments/Updates
6.5 Bachem
6.5.1 Bachem Corporation Information
6.5.2 Bachem Description and Business Overview
6.5.3 Bachem Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bachem Bioequivalent Peptide Drugs Product Portfolio
6.5.5 Bachem Recent Developments/Updates
6.6 Bharat Pharmaceuticals
6.6.1 Bharat Pharmaceuticals Corporation Information
6.6.2 Bharat Pharmaceuticals Description and Business Overview
6.6.3 Bharat Pharmaceuticals Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bharat Pharmaceuticals Bioequivalent Peptide Drugs Product Portfolio
6.6.5 Bharat Pharmaceuticals Recent Developments/Updates
6.7 Kingpep Biotechnology
6.6.1 Kingpep Biotechnology Corporation Information
6.6.2 Kingpep Biotechnology Description and Business Overview
6.6.3 Kingpep Biotechnology Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kingpep Biotechnology Bioequivalent Peptide Drugs Product Portfolio
6.7.5 Kingpep Biotechnology Recent Developments/Updates
6.8 Ambio Pharmaceuticals
6.8.1 Ambio Pharmaceuticals Corporation Information
6.8.2 Ambio Pharmaceuticals Description and Business Overview
6.8.3 Ambio Pharmaceuticals Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Ambio Pharmaceuticals Bioequivalent Peptide Drugs Product Portfolio
6.8.5 Ambio Pharmaceuticals Recent Developments/Updates
6.9 Jiangsu Sinopep Allsino Biopharmaceutical
6.9.1 Jiangsu Sinopep Allsino Biopharmaceutical Corporation Information
6.9.2 Jiangsu Sinopep Allsino Biopharmaceutical Description and Business Overview
6.9.3 Jiangsu Sinopep Allsino Biopharmaceutical Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Jiangsu Sinopep Allsino Biopharmaceutical Bioequivalent Peptide Drugs Product Portfolio
6.9.5 Jiangsu Sinopep Allsino Biopharmaceutical Recent Developments/Updates
6.10 Shanghai Shyndec Pharmaceutical
6.10.1 Shanghai Shyndec Pharmaceutical Corporation Information
6.10.2 Shanghai Shyndec Pharmaceutical Description and Business Overview
6.10.3 Shanghai Shyndec Pharmaceutical Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Shanghai Shyndec Pharmaceutical Bioequivalent Peptide Drugs Product Portfolio
6.10.5 Shanghai Shyndec Pharmaceutical Recent Developments/Updates
6.11 Shenzhen Salubris Pharmaceuticals
6.11.1 Shenzhen Salubris Pharmaceuticals Corporation Information
6.11.2 Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Description and Business Overview
6.11.3 Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Product Portfolio
6.11.5 Shenzhen Salubris Pharmaceuticals Recent Developments/Updates
6.12 Shanghai United Cell Biotechnology
6.12.1 Shanghai United Cell Biotechnology Corporation Information
6.12.2 Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Description and Business Overview
6.12.3 Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Product Portfolio
6.12.5 Shanghai United Cell Biotechnology Recent Developments/Updates
6.13 Shenzhen JYMed Technology
6.13.1 Shenzhen JYMed Technology Corporation Information
6.13.2 Shenzhen JYMed Technology Bioequivalent Peptide Drugs Description and Business Overview
6.13.3 Shenzhen JYMed Technology Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Shenzhen JYMed Technology Bioequivalent Peptide Drugs Product Portfolio
6.13.5 Shenzhen JYMed Technology Recent Developments/Updates
6.14 Wuxi Asiapeptide Biotechnology
6.14.1 Wuxi Asiapeptide Biotechnology Corporation Information
6.14.2 Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Description and Business Overview
6.14.3 Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Product Portfolio
6.14.5 Wuxi Asiapeptide Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bioequivalent Peptide Drugs Industry Chain Analysis
7.2 Bioequivalent Peptide Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bioequivalent Peptide Drugs Production Mode & Process
7.4 Bioequivalent Peptide Drugs Sales and Marketing
7.4.1 Bioequivalent Peptide Drugs Sales Channels
7.4.2 Bioequivalent Peptide Drugs Distributors
7.5 Bioequivalent Peptide Drugs Customers
8 Bioequivalent Peptide Drugs Market Dynamics
8.1 Bioequivalent Peptide Drugs Industry Trends
8.2 Bioequivalent Peptide Drugs Market Drivers
8.3 Bioequivalent Peptide Drugs Market Challenges
8.4 Bioequivalent Peptide Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
